NEA Management Company, LLC: 13F holdings
CIK 15128482026Q2
| Positions | 26 |
|---|
| Reported value | $1.6bn |
|---|
| Filed | 2026-08-14 |
|---|
Change since last quarter
| Positions | 26 (+0 vs prior quarter) |
|---|
| Reported value | $1.6bn (-9.7%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| TRVI Trevi Therapeutics, Inc. | 13,222,228 | $246.6m | 15.5% |
| MBX MBX Biosciences, Inc. | 3,614,486 | $199.5m | 12.6% |
| GLUE Monte Rosa Therapeutics, Inc. | 7,692,298 | $186.2m | 11.7% |
| CELC Celcuity Inc. | 1,710,561 | $179.0m | 11.3% |
| Spyglass Pharma, Inc. | 7,392,301 | $164.6m | 10.4% |
| SVRA Savara, Inc. | 24,471,264 | $150.7m | 9.5% |
| ZBIO Zenas BioPharma, Inc. | 4,023,219 | $102.1m | 6.4% |
| COUR Coursera, Inc. | 12,867,769 | $72.6m | 4.6% |
| AUPH Aurinia Pharmaceuticals, Inc. | 3,969,834 | $67.4m | 4.2% |
| CRISPR Therapeutics AG | 1,058,570 | $57.7m | 3.6% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1512848")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples